Abstract
Background SARS-CoV-2 is a rapidly spreading coronavirus with a high incidence of severe upper respiratory infection that first presented in Wuhan, China in December 2019. Many factors have been identified as risk factors for SARS-CoV-2, with much attention being paid to body mass index (BMI). Little investigation has been done to investigate dysregulation of lipid profiles and diabetes, which are often comorbid in high BMI patients.
Objective This study seeks to describe the impact of BMI, HDL, LDL, ApoA, ApoB, triglycerides, hemoglobin A1c (HbA1c), diabetes, alcohol and red wine intake on the odds of testing positive for SARS-CoV-2 in UK Biobank (UKB) study participants.
Methods We examined the effect of BMI, lipid profiles, diabetes and alcohol intake on the odds of testing positive for SARS-Cov-2 among 9,005 UKB participants tested for SARS-CoV-2 from March 16 through July 14, 2020. Odds ratios and 95% confidence intervals were computed using logistic regression adjusted for age, sex and ancestry.
Results Higher BMI, Type II diabetes and HbA1c were associated with increased SARS-CoV-2 odds (p < 0.05) while HDL and ApoA were associated with decreased odds (p < 0.001). Though the effect of BMI, Type II diabetes and HbA1c were eliminated when HDL was controlled, the effect of HDL remained significant when BMI was controlled for. Additionally, red wine intake was associated with reduced odds of testing positive for SARS-CoV-2 (p < 0.05). LDL, ApoB and triglyceride levels were not found to be significantly associated with increased odds.
Conclusion Elevated HDL and ApoA levels and alcohol intake, specifically red wine intake, were associated with reduced odds of testing positive for SARS-CoV-2, while higher BMI, type II diabetes and HbA1c were associated with increased odds. The effects of alcohol, BMI, type II diabetes and HbA1c levels were no longer significant after controlling for HDL, suggesting that these effects may be mediated in part through regulation of HDL levels. In summary, our study corroborates the emerging picture that high HDL levels may confer protection against SARS-CoV-2.
Highlights
Higher baseline HDL levels were associated with reduced odds of testing positive for SARS-CoV-2.
BMI, Type II diabetes and hemoglobin A1C levels were associated with elevated odds of testing positive for SARS-CoV-2, but this effect was abrogated when controlling for HDL.
Red wine intake was associated with reduced odds of testing positive for SARS-CoV-2, although this effect may in part be moderated by HDL.
Baseline LDL and Triglyceride levels were not associated with increased odds of testing positive for SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was conducted using the UK Biobank Resource under Application Number 49852. This work was supported by 5T32GM092237-10 to RS, NIGMS R01GM118557, NHLBI R01HL135129 to CCH, and NHLBI 1U01HL137181 to JP. The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB # for this study is HF-00088022 Phenome-wide association study (PheWAS) using UK Biobank Database. It was deemed NOT HUMAN RESEARCH.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this research was downloaded from the UK Biobank Resource under Application Number 49852. Copies of the data may be obtained from the UK Biobank Resource. The data access procedure is provided on their website. ( https://www.ukbiobank.ac.uk/wp-content/uploads/2012/09/Access-Procedures-2011-1.pdf )
